Published in Clin Exp Med on August 23, 2014
Dickkopf-1 is a master regulator of joint remodeling. Nat Med (2007) 7.29
Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) (2012) 2.38
Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) (2011) 1.67
Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis (2006) 1.64
Pro-inflammatory cytokines TNF-related weak inducer of apoptosis (TWEAK) and TNFalpha induce the mitogen-activated protein kinase (MAPK)-dependent expression of sclerostin in human osteoblasts. J Bone Miner Res (2009) 1.36
Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum (1987) 1.34
Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. Rheumatology (Oxford) (2005) 1.33
Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci (2006) 1.22
A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. Arthritis Res Ther (2007) 1.13
The skeleton in rheumatoid arthritis: common mechanisms for bone erosion and osteoporosis? J Rheumatol (2000) 1.07
From bone biology to clinical outcome: state of the art and future perspectives. Ann Rheum Dis (2010) 1.02
Methotrexate concentrations in synovial membrane and trabecular and cortical bone in rheumatoid arthritis patients. Arthritis Rheum (1994) 0.97
Methotrexate osteopathy in patients with osteosarcoma. Radiology (1997) 0.94
The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats. Arthritis Rheum (1994) 0.93
Bone metabolism in rheumatoid arthritis; relation to disease activity. Br J Rheumatol (1993) 0.92
Effects of methotrexate on human osteoblasts in vitro: modulation by 1,25-dihydroxyvitamin D3. J Bone Miner Res (1995) 0.91
Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis. J Rheumatol (1988) 0.86
Methotrexate maintains bone mass by preventing both a decrease in bone formation and an increase in bone resorption in adjuvant-induced arthritic rats. Bone (1997) 0.82
Comparison of the effects of adriamycin and methotrexate on orthotopic and induced heterotopic bone in rats. J Orthop Res (1990) 0.82
Insufficiency fracture of the distal tibia mimicking arthritis in a rheumatoid arthritis patient. The possible role of methotrexate treatment. Clin Exp Rheumatol (1995) 0.82
Methotrexate osteopathy in rheumatic disease. Ann Rheum Dis (1993) 0.80
Osteoporosis in rheumatoid arthritis: what is the role of antirheumatic therapy? Lancet (1994) 0.78
Methotrexate effects on heterotopic bone in rats. Acta Orthop Scand (1987) 0.78
Extra-skeletal effects of bisphosphonates. Joint Bone Spine (2006) 1.59
Osteoblast physiology in normal and pathological conditions. Cell Tissue Res (2010) 1.49
Osteocalcin: skeletal and extra-skeletal effects. J Cell Physiol (2013) 1.31
Vitamin D and the immune system. J Rheumatol (2010) 1.22
Multiprofessional and intrahospital experience for diagnosis and treatment of pulmonary arterial hypertension. Monaldi Arch Chest Dis (2012) 0.95
The death receptor DR5 is involved in TRAIL-mediated human osteoclast apoptosis. Apoptosis (2007) 0.94
Osteoclastogenesis and arthritis. Clin Exp Med (2010) 0.93
Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol (2012) 0.87
Bone effects of biologic drugs in rheumatoid arthritis. Clin Dev Immunol (2013) 0.86
Mast cells in rheumatoid arthritis. Clin Rheumatol (2006) 0.85
Abnormalities of insulin-like growth factor-I signaling and impaired cell proliferation in osteoblasts from subjects with osteoporosis. Endocrinology (2007) 0.85
RANKL/OPG ratio and DKK-1 expression in primary osteoblastic cultures from osteoarthritic and osteoporotic subjects. J Rheumatol (2013) 0.85
Systemic effects of Wnt signaling. J Cell Physiol (2013) 0.84
Macrophages and angiogenesis in rheumatic diseases. Vasc Cell (2013) 0.84
Expression of vascular endothelial growth factor in normal, osteoarthritic and osteoporotic osteoblasts. Clin Exp Med (2011) 0.83
In vitro and in vivo angiogenic activity of osteoarthritic and osteoporotic osteoblasts is modulated by VEGF and vitamin D3 treatment. Regul Pept (2013) 0.81
Immunomodulatory effects of vitamin D in peripheral blood monocyte-derived macrophages from patients with rheumatoid arthritis. Clin Exp Med (2013) 0.81
Nailfold capillaroscopic findings in systemic sclerosis related lung fibrosis and in idiopathic lung fibrosis. Joint Bone Spine (2010) 0.81
TNF-related apoptosis-inducing ligand (TRAIL) in rheumatoid arthritis: what's new? Clin Exp Med (2012) 0.80
Two cases of distal extremity swelling with pitting oedema in psoriatic arthritis: the different pathological mechanisms. Rheumatol Int (2009) 0.79
Juvenile idiopathic arthritis: an update on clinical and therapeutic approaches. Ann Ital Med Int (2006) 0.77
Neridronate and human osteoblasts in normal, osteoporotic and osteoarthritic subjects. Clin Rheumatol (2005) 0.77
Putative effects of potentially anti-angiogenic drugs in rheumatic diseases. Eur J Clin Pharmacol (2013) 0.76
Impact of biological therapy on spondyloarthritis. Eur J Clin Pharmacol (2014) 0.76
Subspecificities of anticentromeric protein A antibodies identify systemic sclerosis patients at higher risk of pulmonary vascular disease. Medicine (Baltimore) (2016) 0.75
Correction: Relationship between Body Mass Composition, Bone Mineral Density, Skin Fibrosis and 25(OH) Vitamin D Serum Levels in Systemic Sclerosis. PLoS One (2015) 0.75
Botulinum toxin type A in the treatment of focal hand dystonia after surgical treatment for thumb duplication. Orthopedics (2009) 0.75
Why TNF-α inhibition is not sufficient to avoid juxta-articular erosions in chronic arthritis? Intern Emerg Med (2011) 0.75
Subclinical atherosclerosis and history of cardiovascular events in Italian patients with rheumatoid arthritis: Results from a cross-sectional, multicenter GIRRCS (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. Medicine (Baltimore) (2017) 0.75